Added benefit of linagliptin is not proven

Drug manufacturer deviates from appropriate comparator therapy specified by the G-BA

2012-01-09

(Press-News.org) Linagliptin (trade name: Trajenta®) has been approved since August 2011 to improve blood glucose control ("glycaemic control") in adults with type 2 diabetes mellitus whose elevated blood glucose levels are inadequately controlled by diet and exercise. It is an option for patients who do not tolerate or should not take the usual treatment with the drug metformin. Moreover, linagliptin can be added if treatment with metformin alone is not sufficient.

In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether linagliptin offers an added benefit versus the appropriate comparator therapy specified by the Federal Joint Committee (G-BA). No such added benefit can be inferred from the dossier, as the drug manufacturer deviated from the G-BA's specifications and chose a different comparator therapy.

Approval status distinguishes between three treatment situations

The appropriate comparator therapy specified by the G-BA distinguishes between three treatment situations:

* Administration of linagliptin alone (monotherapy) as a substitute for metformin if this drug is not tolerated by patients or should not be taken because of impaired kidney function. To assess the added benefit, linagliptin monotherapy should be compared with a drug from the sulfonylurea class (glibenclamide or glimepiride).

* Dual therapy combines linagliptin and metformin and is indicated if treatment with metformin alone is insufficient to control blood glucose levels. To assess the added benefit, dual therapy with linagliptin should be compared with a combination of metformin and a sulfonylurea (glibenclamide or glimepiride).

* Triple therapy combines linagliptin, metformin and a sulfonylurea and is used if dual therapy with metformin and a sulfonylurea is no longer a sufficient treatment option. To assess the added benefit, triple therapy should be compared with a combination of insulin and metformin.

Drug manufacturer chose a gliptin as comparator therapy

In its dossier, the manufacturer compared linagliptin with a different drug from the gliptin class (sitagliptin) in all three treatment situations and thereby deviated from the specifications of the G-BA. However, in IQWiG's opinion, the manufacturer insufficiently justified this deviation. For the dossier assessment IQWiG therefore uses the appropriate comparator therapy specified by the G-BA.

In the dossier, the manufacturer makes no statements on the extent and probability of an added benefit of linagliptin versus the appropriate comparator therapy specified by the G-BA. Studies that would have been relevant for this purpose were explicitly excluded from the assessment. The manufacturer's dossier therefore provides no proof of an added benefit of linagliptin versus the G-BA's appropriate comparator therapy. This applies to all three treatment situations mentioned above, that is, monotherapy, dual and triple combination therapy.

In the dossier the manufacturer did not determine an added benefit of linagliptin versus the comparator therapy they had chosen themselves (sitagliptin).

G-BA decides on the extent of added benefit

The procedure for inferring the overall conclusion on the extent of added benefit is a proposal from IQWiG. The G-BA, which has opened a formal commenting procedure, will decide on the extent of added benefit.

### The website gesundheitsinformation.de, which is issued by IQWiG, provides easily understandable brief information (German version, http://www.gesundheitsinformation.de/typ-2-diabetes-welche-vor-oder-nachteile-hat-linagliptin.803.de.html).

The G-BA website contains both general information (http://www.english.g-ba.de/special-topics/pharmaceuticals/benefitassessment/) on benefit assessments pursuant to §35a Social Code Book V and specific information on the assessment of linagliptin (German version, http://www.g-ba.de/informationen/nutzenbewertung/20/).

ELSE PRESS RELEASES FROM THIS DATE:

Abiraterone: Indication of considerable added benefit in certain patients

2012-01-09

Abiraterone (trade name: Zytiga®) has been approved since September 2011 for men with metastatic prostate cancer that is no longer responsive to hormone therapy and progresses further during or after therapy with the cytostatic drug docetaxel. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether abiraterone offers an added benefit compared with the present standard therapy. IQWiG finds an indication of a considerable added ...

Researchers find malignancy-risk gene signature for early-stage non-small cell lung cancer

2012-01-09

TAMPA, Fla. (Jan. 6, 2012) – A malignancy-risk gene signature developed for breast cancer has been found to have predictive and prognostic value for patients with early stage non-small cell lung cancer. The advancement was made by researchers at Moffitt Cancer Center in Tampa, Fla., who published their study results in a recent issue of the Journal of the National Cancer Institute. According to corresponding author Dung-Tsa Chen, Ph.D., associate member with the Moffitt Biostatistics program, non-small cell lung cancer (NSCLC) accounts for 80-90 percent of all lung cancers. ...

Hybrid silkworms spin stronger spider silk

2012-01-09

This week, research was published showing that silk produced by transgenically-engineered silkworms in the laboratory of Malcolm Fraser, Jr., professor of biological sciences at University of Notre Dame, exhibits the highly sought-after strength and elasticity of spider silk. This stronger silk could possibly be used to make sutures, artificial limbs and parachutes. The findings were published in the Proceedings of the National Academy of Sciences and highlighted for their breakthrough in the long search for silk with such mechanical properties. The manuscript was published ...

Mars rover to spend winter at 'Greeley Haven,' named for late ASU geologist Ronald Greeley

2012-01-09

TEMPE, Ariz. - NASA's Mars Exploration Rover Opportunity will spend the next few months during the coldest part of Martian winter at Greeley Haven, an outcrop of rock on Mars recently named informally to honor Ronald Greeley, Arizona State University Regents' professor of planetary geology, who died October 27, 2011. Long passionate about exploring the solar system and Mars in particular, Greeley was involved with many missions to the Red Planet, including Mariners 6, 7, and 9, Viking, Mars Pathfinder, Mars Global Surveyor, and the two Mars Exploration Rovers. He was ...

Experts offer pointers for optimizing radiation dose in pediatric CT

2012-01-09

An article in the January issue of the Journal of the American College of Radiology summarizes methods for radiation dose optimization in pediatric computed tomography (CT) scans. Approximately seven to eight million CT examinations are performed for various pediatric clinical indications per year in the United States. Justification of clinical indication is the most important aspect of reducing radiation dose with CT scanning. A substantial number of pediatric CT scans lack appropriate justification or can be replaced with other imaging modalities with lower or no ionizing ...

The nuclear, biological and climate threat - 2011 reviewed

2012-01-09

In this special issue of the Bulletin of the Atomic Scientists, published by SAGE, experts reflect on 2011 and highlight what to look out for in 2012 in the areas of nuclear energy, nuclear weapons, biosecurity, and climate change. Topics that have made the headlines during the previous 12 months, including the increased tension surrounding Iran's nuclear programme, the aftermath of the Fukushima incident, and the state of US policy on climate change, are analyzed in detail in this special issue. At the Doomsday Clock Symposium on January 9-10 in Washington, DC, the Bulletin's ...

Salk scientists map the frontiers of vision

2012-01-09

There's a 3-D world in our brains. It's a landscape that mimics the outside world, where the objects we see exist as collections of neural circuits and electrical impulses. Now, scientists at the Salk Institute for Biological Studies are using new tools they developed to chart that world, a key step in revolutionizing research into the neurological basis of vision. For the first time, the scientists have produced neuron-by-neuron maps of the regions of the mouse brain that process different kinds of visual information, laying the groundwork for decoding the circuitry ...

Tiny worm points to big promise

2012-01-09

Two related studies from Northwestern University offer new strategies for tackling the challenges of preventing and treating diseases of protein folding, such as Alzheimer's, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis (ALS), cancer, cystic fibrosis and type 2 diabetes. To do its job properly within the cell, a protein first must fold itself into the proper shape. If it doesn't, trouble can result. More than 300 diseases have at their root proteins that misfold, aggregate and eventually cause cellular dysfunction and death. The new Northwestern ...

Tobacco company misrepresented danger from cigarettes

2012-01-09

A new UCSF analysis of tobacco industry documents shows that Philip Morris USA manipulated data on the effects of additives in cigarettes, including menthol, obscuring actual toxicity levels and increasing the risk of heart, cancer and other diseases for smokers. Tobacco industry information can't be taken at face value, the researchers conclude. They say their work provides evidence that hundreds of additives, including menthol, should be eliminated from cigarettes on public health grounds. The article is published in PLoS Medicine http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001145 In ...

Majority groups support assimilation -- except when they're not majorities

2012-01-09

We generally think that views about how to integrate a diverse society depend on people's positions in that society—that is, whether they're in the racial, religious, or cultural majority or a member of a minority. In the U.S., "people tend to believe that blacks prefer pluralism and whites prefer assimilation," says University of Delaware psychologist Eric Hehman. Assimilation asks minorities—whether newly arrived or historically rooted—to drop their cultural identities and adopt the ways of the majority. Pluralism recognizes and even celebrates minority cultures, which ...

Inhibition of cyclooxygenase-2 upregulates the nuclear factor erythroid 2-related factor 2 signaling pathway to mitigate hepatocyte ferroptosis in chronic liver injury

Added benefit of linagliptin is not proven

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: